Core diluted earnings per share vs Novel active substance launches
In 2025, core diluted earnings per share worldwide was 11.1 CHF; novel active substance launches was 79.
Change the pair
Compare different indicators
The series
Over time
Global, spaced by time in 2025 . Different units, drawn on separate scales and clipped to the years both series publish — earlier history stays on each indicator's own page. Read the values, not the heights.
Core diluted earnings per share
Unit: CHF · 1 observation
View the underlying data
| Period | Type | Value |
|---|---|---|
| Q1 2025 | Actual | 11.1 CHF |
Novel active substance launches
Unit: count · 1 observation
View the underlying data
| Period | Type | Value |
|---|---|---|
| 2025 | Actual | 79 |
Shared periods
Side by side
Only one period is published for both series. Comparing anything else would mean comparing different years.
Provenance
Where these numbers come from
Core diluted earnings per share
Core earnings per share calculated on a diluted basis.
2 observations in Global · source organisations: Roche
Novel active substance launches
Total number of novel active substances launched.
2 observations in Global · source organisations: IFPMA, IQVIA
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring